Rapport Therapeutics, Inc. Common Stock
Price Action
Technical Summary
STAGE 2 UPTRENDRapport Therapeutics, Inc. Common Stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 87), indicating clear outperformance against the broad market. Earnings growth of 38% provides fundamental context to the price action. However, price is extended 24% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $36.10 | +10.61% | ABOVE |
| 50 SMA | $32.19 | +24.05% | ABOVE |
| 100 SMA | $30.32 | +31.72% | ABOVE |
| 150 SMA | $29.20 | +36.77% | ABOVE |
| 200 SMA | $26.71 | +49.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RAPP in an uptrend right now?
RAPP has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RAPP is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RAPP overbought or oversold?
RAPP's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is RAPP outperforming the market?
RAPP has a Relative Strength (RS) Rating of 87 out of 99. Yes, RAPP is a market leader, outperforming 87% of all stocks over the past 12 months.
Where is RAPP in its 52-week range?
RAPP is trading at $39.93, which is 94% of its 52-week high ($42.27) and 93% above its 52-week low ($7.73).
How volatile is RAPP?
RAPP has a Beta of 1.55 and 52-week volatility of 77%. It's more volatile than the S&P 500 - expect bigger swings.